Welcome to our dedicated page for Rocket Lab SEC filings (Ticker: RKLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Rocket Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Rocket Lab's regulatory disclosures and financial reporting.
Morgan Stanley Smith Barney LLC reported proposed sales of restricted common stock under Rule 144, listing 31,908 shares and 2,021 shares dated 05/22/2026 tied to restricted stock vesting. The filings identify the issuer as the counterparty and show transactions associated with compensation vesting on 05/22/2026.
Slusky Alexander R reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Alexander R. Slusky reported an equity grant of 2,482 restricted stock units (RSUs). These RSUs were granted under Rocket Lab’s Amended and Restated Non-Employee Director Compensation Policy and the 2021 Stock Option and Incentive Plan as part of director compensation.
The RSUs will vest in full on the earlier of the company’s next Annual Meeting of Stockholders or the one-year anniversary of the grant date, subject to his continued board service. Following this grant, Slusky directly holds 61,331 shares of common stock and indirectly holds 434,675 shares through Abalone Cove LLLP, a partnership he and his spouse own.
Saintil Merline reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Merline Saintil received a grant of 2,482 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and increase her direct holdings to 264,385 shares. The RSUs will vest in full on the earlier of the company’s next annual meeting of stockholders or the one-year anniversary of the grant date, as long as she continues serving on the Board.
Possenriede Kenneth R reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Kenneth R. Possenriede received an award of 2,482 shares of Common Stock in the form of restricted stock units. The grant was made at no cash cost to him and increases his direct holdings to 96,660 shares. These RSUs will vest in full on the earlier of the company’s next Annual Meeting of Stockholders or the one-year anniversary of the grant date, as long as he continues serving on the Board.
Olson Jon A reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Jon A. Olson reported an equity grant of 2,482 restricted stock units (RSUs) of common stock at no cost. The RSUs were granted under Rocket Lab’s non-employee director compensation policy and 2021 equity plan on May 20, 2026. They will vest in full on the earlier of the company’s next annual meeting of stockholders or the one-year anniversary of the grant date, as long as Olson continues serving on the board. After this award, he directly holds 348,112 shares of Rocket Lab common stock.
Frank Edward H. reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Frank Edward H. received an equity grant of 2,482 restricted stock units (RSUs). These RSUs were awarded under Rocket Lab’s Amended and Restated Non-Employee Director Compensation Policy and its 2021 Stock Option and Incentive Plan as part of his board compensation.
The RSUs will vest in full on the earlier of the company’s next Annual Meeting of Stockholders or the one-year anniversary of the grant date, as long as he continues serving on the board through that date. Following this grant, he holds 144,986 shares of Rocket Lab common stock directly.
Armagno Nina reported acquisition or exercise transactions in this Form 4 filing.
Rocket Lab Corp director Nina Armagno received an equity grant as part of her board compensation. She was awarded 2,482 shares of Common Stock in the form of restricted stock units at a stated price of $0.0000 per share. Following this grant, she holds 111,422 shares directly. The RSUs will vest in full on the earlier of the company’s next Annual Meeting of Stockholders or the one-year anniversary of the grant date, subject to her continuous service on the Board.
Rocket Lab Corporation reported results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected Class II director Edward H. Frank for a term expiring at the 2029 annual meeting, with 297,673,425 votes for, 55,896,708 withheld, and 116,546,800 broker non-votes.
Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 467,440,986 votes for, 1,737,306 against, and 938,641 abstentions. They also approved, on a non-binding advisory basis, named executive officer compensation and a subsidiary merger eliminating a pass-through voting provision at Rocket Lab USA, Inc.
Rocket Lab Corporation entered an equity distribution agreement that allows sales of common stock and related forward transactions with an aggregate offering price of up to $3,000,000,000.
The company can sell shares through multiple banks as agents or principals and also use initially priced and collared forward sale agreements. Rocket Lab will receive cash only when these forward transactions are physically settled or when collared components are prepaid or settled, and it will pay commissions of up to 2.00% on sales under the program.
Rocket Lab Corporation registered an at-the-market equity program to offer up to $3,000,000,000 of common stock under a prospectus supplement dated May 20, 2026. The company may sell shares through appointed sales agents or enter into forward and collared forward transactions with specified financial counterparties.
The supplement states Rocket Lab will not initially receive proceeds from sales of borrowed hedging shares, expects to receive cash upon physical settlement or certain prepayments, and may use net proceeds to fund growth, potential acquisitions and general corporate purposes. The offering is subject to FINRA Rule 5121 conflict-of-interest procedures.